<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4024">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748185</url>
  </required_header>
  <id_info>
    <org_study_id>20-012589</org_study_id>
    <nct_id>NCT04748185</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies</brief_title>
  <official_title>Immunogenicity and Safety of Commercially Available Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Hematologic Malignancies and Associated Precursor Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      D1. Primary Objective:&#xD;
&#xD;
      1. Determine the immunogenicity of FDA approved COVID-19 vaccination in patients with&#xD;
      hematologic malignancies&#xD;
&#xD;
      D2. Secondary Objectives:&#xD;
&#xD;
        1. Assess the safety of FDA approved COVID-19 vaccination in patients with hematologic&#xD;
           malignancies&#xD;
&#xD;
        2. Analyze the kinetics of immunogenic response over time after receipt of the COVID-19&#xD;
           vaccination&#xD;
&#xD;
        3. Compare the immunogenicity of different COVID-19 vaccinations that will be approved by&#xD;
           the FDA&#xD;
&#xD;
        4. Analyze advanced flow immunophenotyping of innate and adaptive immune blood cells in all&#xD;
           participants and correlate with response to vaccination&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral Immunogenicity</measure>
    <time_frame>Assessed 14 days following the second dose of the vaccine</time_frame>
    <description>Number of participants who have detectable antibodies to SARS-Co-V2 vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular Immunogenicity</measure>
    <time_frame>Assessed 14 days following the second dose of the vaccine</time_frame>
    <description>Number of participants who have a SARS-CoV-2 specific memory B cell ELISPOT response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular Immunogenicity</measure>
    <time_frame>Assessed 14 days following the second dose of the vaccine</time_frame>
    <description>Number of participants who have a SARS-CoV-2 specific IFNÎ³ ELISPOT T cell response</description>
  </primary_outcome>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Monoclonal B-Cell Lymphocytosis</condition>
  <condition>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</condition>
  <condition>B-cell Non Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients will submit peripheral blood samples a) prior to first dose of vaccination; b)&#xD;
        prior to receipt of the second dose of vaccination; c) 14 days following the second dose;&#xD;
        and d) 3, 6 and 12 months following the first dose of the vaccination. For patients at time&#xD;
        points a, b, and c blood samples can be collected up to 3 days prior; and at time point d&#xD;
        +/- 10 days.&#xD;
&#xD;
        Patients who are seen at Mayo Clinic in Rochester, MN can collect their blood through a&#xD;
        venipuncture at the clinic. For patients who are to receive vaccination locally, a blood&#xD;
        kit will be mailed for the patients to get research bloods collected and sent to Mayo&#xD;
        Clinic.&#xD;
&#xD;
        All patients will also complete a diary of adverse reactions (Appendix I) daily for 7 days&#xD;
        after receipt of each dose of the vaccine. Patients will be asked to contact their primary&#xD;
        care provider or hematologist if they have any side effects from the vaccination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must not have received any prior COVID-19 vaccination&#xD;
&#xD;
          2. Patients must have any one of the following diagnosis:&#xD;
&#xD;
             a. Monoclonal B-cell lymphocytosis b. Chronic lymphocytic leukemia/small lymphocytic&#xD;
             lymphoma c. B-cell Non-Hodgkin's lymphoma: i. Follicular lymphoma ii. Mantle cell&#xD;
             lymphoma iii. Diffuse large B-cell lymphoma iv. Marginal zone lymphoma v. Burkitt&#xD;
             lymphoma vi. Double hit/triple hit lymphoma vii. Lymphoplasmacytic&#xD;
             lymphoma/Waldenstrom's macroglobulinemia d. Hodgkin lymphoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of any vaccination (e.g., influenza, recombinant zoster) 2 weeks prior to&#xD;
             registration&#xD;
&#xD;
          2. Prior chemotherapy, immunotherapy or oral agent therapy that was completed &gt;12 months&#xD;
             prior to enrollment. NOTE: patients who are on oral agents for the treatment of their&#xD;
             underlying malignancy will be allowed. Some of these medication classes include Bruton&#xD;
             tyrosine kinase inhibitor (BTKi), BCL2 antagonists, PI3 kinase inhibitors,&#xD;
             immunomodulatory agents, among others. Please contact the Principal Investigator for&#xD;
             any clarification about these medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameer Parikh, M.B.B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanner W Reicks, BSHS</last_name>
    <phone>608-377-1647</phone>
    <email>Reicks.tanner@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julianne Lunde, MA</last_name>
      <phone>507-266-2657</phone>
      <email>lunde.julianne@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Sameer Parikh, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sameer A. Parikh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Covid-19 Vaccine</keyword>
  <keyword>CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphocytosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

